Core Viewpoint - MIRXES-B has seen a significant increase in stock price, reaching a new high following the announcement of a collaboration with PT DIASTIKA BIOTEKINDO for cancer diagnostics in Indonesia [1][2] Group 1: Company Developments - On August 15, MIRXES-B announced a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] - The memorandum is valid for 12 months from the date of signing [1] Group 2: Market Expansion Strategy - Through the partnership with PT DIASTIKA BIOTEKINDO, the company aims to enter the Indonesian market by deploying blood-based microRNA or multi-omics cancer detection devices for prevalent cancers such as gastric and lung cancer [2] - The collaboration will leverage local policies in Indonesia, such as tax incentives for local content, and regulatory flexibility under ASEAN-centered medical device frameworks [2] - Indonesia is viewed as a pilot region for expanding operations to Southeast Asia, the Middle East, North Africa, and other areas with similar cancer profiles and healthcare structures [2]
MIRXES-B涨超8%创新高 以部署基于血液microRNA等检测设备方式进军印尼市场